New drug mimics IVIg to fight low platelet disorder

NCT ID NCT07095127

Recruiting now Disease control Sponsor: Nuvig Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called NVG-2089 in 30 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is designed to work like IVIg, calming the immune system. Researchers will check for side effects and see if it raises platelet counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NVG-2089
What this could lead to: If successful, this could provide a new treatment option for people with immune thrombocytopenia, helping to raise platelet counts and reduce bleeding risk.
What could go wrong: This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve platelet counts significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

East Carolina University
RECRUITING

Greenville, North Carolina, 27834, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.